Ergomed plc, a leading provider of specialised services to the pharmaceutical industry, is headquartered in Great Britain. Founded in 1997, the company has established a strong presence in key operational regions, including Europe and North America. Ergomed focuses on two main business areas: drug development and post-marketing services, offering a unique blend of expertise that enhances the efficiency of clinical trials. With a commitment to quality and innovation, Ergomed provides a range of core services, including clinical research, pharmacovigilance, and regulatory affairs. The company has achieved notable milestones, such as its successful listing on the London Stock Exchange, solidifying its position as a trusted partner in the life sciences sector. Ergomed's dedication to tailored solutions and client satisfaction sets it apart in a competitive market.
How does Ergomed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ergomed's score of 32 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Ergomed reported total carbon emissions of approximately 46,150 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions were about 730 kg CO2e, primarily from stationary combustion. Scope 2 emissions, related to purchased electricity, accounted for approximately 14,290 kg CO2e. The most significant contributions came from Scope 3 emissions, which totalled around 34,270 kg CO2e, with business travel contributing about 17,290 kg CO2e and upstream transportation and distribution adding approximately 18,980 kg CO2e. Comparatively, in 2021, Ergomed's total emissions were about 60,640 kg CO2e, indicating a reduction of approximately 14,490 kg CO2e year-on-year. This reduction reflects a commitment to improving sustainability practices, although no specific reduction targets or initiatives have been documented. Ergomed's emissions data is sourced from Ergomed Group Limited, with no cascading from a parent company. The company has not set any Science-Based Targets Initiative (SBTi) reduction targets or made specific climate pledges, indicating a potential area for future commitment in climate action. Overall, Ergomed's emissions profile highlights the importance of addressing Scope 3 emissions, which represent a significant portion of their carbon footprint.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 60 | 000 | 
| Scope 2 | 25,450 | 00,000 | 
| Scope 3 | 43,740 | 00,000 | 
Ergomed's Scope 3 emissions, which decreased by 17% last year and decreased by approximately 17% since 2021, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 71% of total emissions under the GHG Protocol, with "Upstream Transportation & Distribution" being the largest emissions source at 52% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ergomed has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
